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Staged bilateral carotid stenting, an effective
strategy in high-risk patients – insights from
a prospective multicenter trial
Nicolas Diehm, MD,a,f Barry T. Katzen, MD,a Sriram S. Iyer, MD,b
Christopher J. White, MD,c L. Nelson Hopkins, MD,d and Lynne Kelley, MD,e on behalf of the
BEACH investigators, Miami, Fla; New York and Buffalo, NY; New Orleans, La; Natick, Mass; and Bern,
Switzerland
Objective: To prospectively evaluate outcomes of high-risk patients undergoing bilateral carotid artery stenting (CAS).
Methods: A total of 747 patients at increased risk for carotid endarterectomy (CEA) were enrolled in a prospective registry
at 47 US sites of the Boston Scientific EPI: A Carotid Stenting Trial for Risk Surgical Patients (BEACH) trial. Among
them, 78 (10.4%) patients underwent contralateral CAS > 30 days after the primary CAS procedure. Patients were
followed at 1, 6, and 12 months, and annually thereafter for 3 years. The primary endpoint was the cumulative incidence
of non Q-wave myocardial infarction within 24 hours, periprocedural (<30 days) death, stroke or Q-wave MI, and late
ipsilateral stroke or death due to neurological events from 31 days up to 12 months. The bilateral patients are
independent from the pivotal cohort.
Results:Mean follow-up was 885  320 days in the bilateral and 861  343 in the pivotal group. The primary endpoint
occurred in 6.8% (5/73) of the bilateral patients and 8.9% (40/447) of the pivotal group (P  .66). There were no
statistically significant differences between the bilateral and the pivotal groups with regard to any of the components of
the primary or secondary endpoints. The univariate 1-year major adverse event (MAE) free survival was 93.6% and 91.6%
in the bilateral and pivotal groups, respectively (P  .55). Multivariate logistic regression analysis with adjustment for
various clinical baseline factors revealed no differences in the primary endpoint when comparing the bilateral with the
pivotal groups at 30 days (odds ratio [OR]: 0.8673, 95% confidence interval [CI] 0.4590-1.6389, P .66) or 1 year (OR:
0.9102, 95% CI 0.5503-1.5053, P  .73).
Conclusions: Bilateral carotid stenting is an effective treatment strategy in patients determined to be at high-risk for CEA
with no increase inmorbidity or mortality results extended out to one year in a prospective multicenter trial. ( J Vasc Surg
2008;47:1227-34.)Large-scale randomized trials have demonstrated that
carotid endarterectomy (CEA) is an effective treatment for
the prevention of cerebrovascular events in patients with
moderate to severe symptomatic1,2 and asymptomatic3 ca-
rotid artery stenosis. Carotid artery stenting (CAS) with
embolic protection is increasingly regarded a treatment
alternative in patients with carotid artery stenosis at high
surgical risk.4-7 Bilateral carotid stenosis is encountered in
up to 51% of patients undergoing CAS and its prevalence is
expected to increase as life expectancy increases.6,8-10 De-
spite encouraging single-center experiences,11,12 patients
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doi:10.1016/j.jvs.2008.01.035with bilateral carotid artery disease are presumed at high
risk for revascularization and have thus been excluded from
most prospective trials. Therefore, data on the safety of
bilateral CAS is currently scarce.
The purpose of the present study was to compare
midterm results of high surgical risk patients undergoing
bilateral carotid artery stenting to those undergoing unilat-
eral treatment in a prospective, multicenter, single arm trial.
Our hypothesis was that outcomes of patients undergoing
staged bilateral CAS would be noninferior to those under-
going unilateral treatment.
METHODS
Study design. Between February 2002 and December
2003, 747 patients at increased risk for CEA were enrolled
in the BEACH trial at 47 US centers. The trial was designed
to evaluate the safety and efficacy of the Carotid Wallstent
with the Filterwire EX/EZ cerebral protection system in
patients with anatomic and/or comorbid conditions that
placed them at high risk for adverse events with carotid
endarterectomy. Enrolment was divided into two separate
phases: the roll-in phase and the pivotal/bilateral phase.
The bilateral subgroup was designed to be evaluated inde-
pendent from the pivotal unilateral population. The proto-
col was approved by the Institutional Review Boards of all
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obtained from patients prior to enrolment. The trial com-
plied with the Declaration of Helsinki and results are
reported on the National Institutes of Health website
(Clintrials.gov, Identifier NCT00316108). Investigator
training included review of animal studies, on-site proctor-
ing to achieve competence in device implantation, and
general training on the protocol.
Patient selection. Inclusion and exclusion criteria, de-
scription of CAS techniques and devices used as well as
30-day and 1-year results of the entire patient cohort are
reported elsewhere.6,7 Briefly, eligible patients with carotid
disease were required to meet general criteria plus at least
one definition of high-risk for surgery based on specific
anatomic and comorbid clinical criteria to be included in
the BEACH trial. The common carotid artery (CCA),
carotid bifurcation, or internal carotid artery (ICA) had to
be4 mm and9 mm in diameter, with50% stenosis by
angiography in symptomatic patients and 80% in asymp-
tomatic patients as assessed by quantitative angiography
using the North American Symptomatic Carotid Endarter-
ectomy Trial (NASCET) methodology.2
Patients diagnosed with bilateral carotid artery disease
requiring treatment for both ipsilateral and contralateral
disease at the time of enrolment were entered in the
BEACH bilateral registry. For inclusion in this registry, the
ipsilateral lesion had to comply with all above-mentioned
general inclusion and exclusion criteria that classified pa-
tients at high risk for surgery. The contralateral lesion was
required to meet the inclusion criteria stenosis threshold for
stroke prevention independent of the risk for surgery.
Both stent procedures were conducted in accordance
with the BEACH trial protocol. The most symptomatic
stenosed artery was treated first, identified as the primary
lesion (also referred to as the ipsilateral lesion), whereas the
second stent procedure was required to be staged and
scheduled 30 days after the first target lesion procedure
(referred to as the contralateral lesion). In patients where
both lesions were asymptomatic and of similar degrees of
stenosis, the carotid supplying the dominant hemisphere
was treated first.
Carotid stent procedure. Procedural details have pre-
viously been reported elsewhere.6,7 Briefly, CAS was
performed using the Carotid WALLSTENT and the
FilterWire EX/EZ distal embolic protection system (Bos-
ton Scientific Corporation, Natick, Mass). Before stent place-
ment, patients received aspirin (325 mg/day starting 72
hours before) plus a loading dose of clopidogrel (450 mg) if
patients were previously not on clopidogrel. Ticlopidine (250
mg twice daily) was substituted in patients unable to tolerate
clopidogrel. After sheath placement, heparin was adminis-
tered and supplemented as needed to maintain an activated
clotting time of 275 seconds or 200 seconds when a
glycoprotein IIb/IIIa receptor inhibitor was administered.
Glycoprotein IIb/IIIa receptor inhibitors were not man-
dated by protocol and were used at the operator’s discre-
tion. Following the procedure, patients received aspirin
(325 mg daily) indefinitely and clopidogrel (75 mg daily)or ticlopidine (250 mg twice daily) for 30 days. For the
bilateral registry group, both stenting procedures were
conducted in accordance with this protocol.
Follow-up. All patients were examined before (within
7 days) and after the procedure (per protocol, within 24
hours and at the time of any change in clinical symptoms)
by an independent neurologist or neurosurgeon certified in
the administration of the National Institutes of Health
Stroke Scale (NIHSS). All patients underwent carotid du-
plex ultrasonography before the procedure and prior to
discharge. Independent ultrasound and angiographic core
laboratories provided review of all studies throughout the
course of the trial and validation of site-determined entry
criteria.6 Follow-up included carotid duplex ultrasonogra-
phy as well as independent neurologic examination using
the NIH stroke scale at 1, 6, and 12 months, and yearly
thereafter through 5 years. Adverse events were adjudicated
by an independent Clinical Events Committee.
Endpoint definitions. The primary composite end-
point was non Q-wave myocardial infarction (MI) within
24 hours following CAS, periprocedural (30 days) death,
stroke, or Q-wave MI and late ipsilateral stroke or death
due to neurological events from 31 days up to 12 months
follow-up.6,7 Secondary solitary endpoints comprised
death (neurologic, cardiac, and general), stroke (ipsilateral,
contralateral, major and minor ischemic, and hemorrhagic)
and Q-wave MI. Technical success was calculated based on
the number of attempts to place the system (FilterWire plus
WALLSTENT). Adverse events were adjudicated by an
independent Clinical Events Committee. For the bilateral
group, the late ipsilateral event was relative to the primary
target lesion.
Stroke was defined as a new focal neurological deficit of
presumed vascular origin persisting more than 24 hours,
with a neuro-imaging study excluding a different etiology.
It included patients presenting with clinical signs and symp-
toms suggestive of subarachnoid hemorrhage, intracerebral
hemorrhage, or cerebral infarction. Strokes were catego-
rized as ipsilateral or contralateral, periprocedural (30
days) or late (31 days from the procedure), and as major
or minor. A major stroke was a stroke that was present after
7 days and increased the NIHSS of the patient by 4
points. A minor stroke was a stroke that resolved com-
pletely within 7 days or increased the NIHSS of the patient
by 3 points. A transient ischemic attack was a focal
ischemic neurological deficit of abrupt onset and of pre-
sumed vascular etiology that resolved completely within 24
hours of onset.
Definitions for MI included Q-wave and non Q-wave
infarctions. A Q-wave MI was required to have pathologic
Q-waves not present on a previous electrocardiogram
(ECG) in two or more contiguous leads (as determined by
the ECG core laboratory, Harvard Clinical Research Insti-
tute, Boston, Mass). A non Q-wave MI had no new patho-
logic Q-waves on ECG and a total creatinine kinase of
greater than two times the normal with an elevated MB
fraction.
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Postprocedural restenosis was defined as a 70% stenosis
by duplex ultrasound and assumed in case of presence of
peak systolic velocity 350 cm/s and an internal carotid
artery to common carotid artery ratio 4.75.13,14 Target
lesion revascularization was at the discretion of the treating
physician.
Statistical methods. Harvard Clinical Research Insti-
tute (HCRI, Boston, Mass) performed data management
and statistical analyses with SAS version 8.2 (SAS Institute
Inc, Cary, NC). All analyses were based on the principle of
intention-to-treat (ITT) and included eligible patients in
whom an attempt was made to place the FilterWire EX/EZ
across the target lesion.
The primary objective of the BEACH trial was to
determine whether the 1-year major adverse event (MAE)
rate in CAS patients at high surgical risk would be less than
or equal to that of the weighted objective performance
criterion (OPC), derived from historic controls of patients
undergoing CEA.6,7 The patient mix was adjusted as indi-
cated below with A and C, representing the proportion
of patients qualified by high-risk anatomic (A) and high-
risk comorbid (C), respectively:
OPC-weighted 4% (A * [OPC-Anatomic])
 (C * [OPC-Comorbid])
The 4% was the margin of equivalence and the remaining
terms represented the 1-year event rate for the same popu-
lation that would have been treated with CEA. For the
purpose of this study and with consent from the Food and
Drug Administration, OPC-Anatomic and OPC-Comorbid
were set to 11% and 15%, respectively.
Continuous variables are presented as mean  1 stan-
dard deviation (SD). Categorical data are given as counts
and percentages. Baseline characteristics were compared by
bivariate analysis using two-sided Fisher exact test for cat-
egorical variables and two-sided Student t test for continu-
ous variables. Bivariate comparisons involving more than
two groups were done using the Kruskal-Wallis test. Cu-
mulative freedom from primary endpoint was assessed by
cumulative outcome estimates according to Kaplan-
Meier15 and compared using log-rank test. Multivariable
logistic regression analysis and Cox proportional hazards
analysis was used to adjust for all baseline characteristics
showing a difference in bivariate analysis with an entry level
of P  .05. A P value .05 was considered to indicate
statistical significance.
RESULTS
There were 189 patients in the roll-in cohort, 480
patients (167 women, mean age 70.9  9.3) in the pivotal
and 78 patients (23 women, mean age 71.1  10 years) in
the bilateral group.
Baseline and procedural characteristics. The pivotal
and bilateral groups differed slightly with regard to symp-
tomatic status, history of other neurological events, history
of previous CEA, current angina, target lesion localization,
and de novo vs recurrent lesion (Table I and Table II). Inthe pivotal group, 41.2% qualified with comorbid risk
factors and 58.8% had high risk anatomic features, resulting
in a value of 16.6% for the weighted OPC. In the bilateral
group, 32.1% qualified with comorbid risk factors and
67.9% had high risk anatomic features, resulting in a value
of 16.3% for the weighted OPC. Technical success was
98.3% in the pivotal group and 97.4% for the first proce-
dure in the bilateral cohort. Mean follow-up was 885 
320 days in the bilateral and 861 343 days in the pivotal
group. Of the 78 patients in the bilateral group, 57 re-
turned to have the contralateral lesion treated.
Clinical outcomes. The primary endpoint was 8.9%
(40/447) with a one-sided 95% upper confidence limit of
11.5% for the pivotal cohort and 6.8% (5/73) with a
one-sided 95% upper confidence limit of 13.9% for the first
procedure of the bilateral cohort, both below their respec-
tive OPCs. There were no statistically significant differences
between the bilateral and the pivotal groups with regard to
any solitary component of the primary endpoint (Table
III). At 5.8%, the primary endpoint for the second proce-
dure in the bilateral cohort was similar to the first procedure
(Table III). The rate of freedom from the primary endpoint
was 93.6% for the first procedure in the bilateral cohort and
91.6% in the pivotal cohort at 1 year (P  .55 by log-rank,
Fig). In a multivariable logistic regression model adjusted
for symptomatic status, history of other neurological
events, history of previous CEA, current angina, target
lesion localization, and de novo vs recurrent lesion, no
significant differences in primary endpoint was found com-
paring the pivotal and first bilateral procedure groups after
30 days (OR: 0.8673, 95% CI: 0.4590-1.6389, P  .66)
and after one year (OR: 0.9102, 95% CI: 0.5503-1.5053,
P  .73), respectively.
The 30-day restenosis rate was 0% for the pivotal group
and 1.3% for the first procedure in the bilateral group (P
.14). One-year restenosis rate was 9.3% in the pivotal and
12.5% in the bilateral group, respectively (P .39). Target
lesion revascularization rate was 0% and 4.7% in the pivotal
group and 0% and 9.7% in the bilateral group after 30 days
(P  NA) and after 1 year (P  .09), respectively.
Duplex ultrasound. Results from follow-up duplex
sonography are outlined in Table IV. No significant differ-
ences in preprocedural and follow-up duplex ultrasound
findings were noted comparing pivotal and bilateral pa-
tients. In the bilateral group, the ICA/CCA peak systolic
velocity (PSV) ratio prior to the procedure was 5.6  3.4
and improved to 1.5 0.7 immediately after the procedure
(P .0001) and remained improved through 1 year. There
was no progression of ICA PSVmaximum over the latter 6
months of follow-up in either cohort.
DISCUSSION
Bilateral carotid disease is frequent6,8-10 and was shown
to substantially increase the risk for complications during
and after unilateral CEA8,16,17 as well as after unilateral
CAS.18 The present prospective series indicates that out-
comes of high-risk patients undergoing staged bilateral
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Patient characteristics Pivotal (n  480) Bilateral (n  78) Pa
Demographics
Age, mean  SD 70.9  9.3 71.1  10.0 .43
Male gender, n (%) 313 (65.2%) 55 (70.5%) .44
Height, mean  SD [inches] 66.9  4.0 67.2  3.9 .27
Weight, mean  SD [lbs] 174.5  37.0 176.7  33.5 .29
White race, n (%) 441 (91.9%) 71 (91.0%) .82
African American race, n (%) 16 (3.3%) 3 (3.8%) .74
Hispanic race, n (%) 8 (1.7%) 4 (5.1%) .07
Asian race, n (%) 12 (2.5%) 0 (0.0%) .39
Other race, n (%) 3 (0.6%) 0 (0.0%) 1.00
Neurological history
Symptomatic carotid lesion 112 (23.3%) 28 (35.9%) .02
Asymptomatic carotid lesion 368 (76.7%) 50 (64.1%)
History of TIA, n (%) 146 (30.4%) 20 (25.6%) .43
History of CVA, n (%) 135 (28.1%) 20 (25.6%) .69
History of other neurologic events, n (%) 42 (8.8%) 14 (17.9%) .02
Known family history of CVA, n (%) 102 (21.3%) 16 (20.5%) 1.00
History of seizures, n (%) 16 (3.3%) 0 (0.0%) .15
Carotid artery disease history
Previous carotid endarterectomy, n (%) 195 (40.6%) 14 (17.9%) .0001
Previous carotid angioplasty, n (%) 6 (1.3%) 8 (0.0%) 1.00
Previous carotid stenting, n (%) 8 (1.7%) 1 (1.3%) 1.00
Previous vertebrobasilar intervention, n (%) 4 (0.8%) 0 (0.0%) 1.00
Cardiac history
Known previous MI, n (%) 170 (35.4%) 26 (33.3%) .79
Known silent ischemia within last month, n (%) 20 (4.2%) 2 (2.6%) .76
Prior CABG, n (%) 167 (34.8%) 29 (37.2%) .70
Known history of primary familial CAD, n (%) 241 (50.2%) 34 (43.6%) .33
Known history of congestive heart failure, n (%) 103 (21.5%) 13 (16.7%) .37
History of coronary valve disease, n (%) 68 (14.2%) 9 (11.5%) .60
Prior coronary valve surgery, n (%) 23 (4.8%) 5 (6.4%) .57
Prior coronary angioplasty, n (%) 140 (29.2%) 26 (33.3%) .50
History of atrial fibrillation/flutter, n (%) 40 (8.3%) 10 (12.8%) .20
Currently experiencing angina, n (%) 75 (15.6%) 4 (5.1%) .01
Mean left ventricular ejection fraction, n (%) 50.4  16.2 48.2  14.4 .21
Other significant disease history
Known current or prior smoking history, n (%) 358 (74.6%) 63 (80.8%) .26
Known history of peripheral vascular disease, n (%) 211 (44.0%) 30 (38.5%) .39
Known history of hypertension, n (%) 429 (89.4%) 73 (93.6%) .31
Known history of hyperlipidemia, n (%) 415 (86.5%) 65 (83.3%) .48
Known history of significant bleeding, n (%) 28 (5.8%) 8 (10.3%) .14
Known history of diabetes mellitus, n (%) 162 (33.8%) 24 (30.8%) .70TIA, transient ischemic attack; CVA, cerebrovascular accident; CABG, coronary artery bypass grafting; CAD, coronary artery disease.
aContinuous data compared by Student t test, categorical data compared by Fisher test.Table II. Target lesion characteristics
Target lesion characteristics
Pivotal
(n  480)
Bilateral first treated side
(n  78)
Bilateral second treated side
(n  57) Pa
Internal carotid artery 424 (88.3%) 75 (96.1%) 55 (100%)b .04
Common carotid artery 56 (11.7%) 3 (3.9%) 0 (0.0%)
Lesion length, mean  SD 15.1  7.2 14.3  5.9 14.8  6.3b .26
De novo lesions 323 (67.3%) 63 (80.8%) 53 (93.0%) .02
Percent DS, mean  SD 71.6  10.7 71.4  9.4 71.1  11.3b .85
ICA/CCA ratio, mean  SD 5.3  3.1 5.6  3.4 4.8  2.4c .48
SD, Standard deviation; ICA/CCA, internal carotid artery/common carotid artery; DS, diameter stenosis.
aP value corresponds to the comparison between the pivotal group and first bilateral procedure.
bData available for 55 patients.
cData available for 27 patients.
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ably with those of patients undergoing unilateral CAS.
While the role of bilateral CEA simultaneously carried
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Fig. Kaplan-Meier analysis of primary endpoint. Cumulative free-
dom from major adverse events did not differ between patients from
the pivotal and from the bilateral group (P .5479 by log-rank).
Table III. One-year rates of study endpoints comparing p
Event
Pivotal
(n  480)
One-year morbidity and mortality 40 (8.9%)
Non Q-wave MI (through 24 h) 4 (0.9%)
Death, stroke, Q-wave MI (through 30 d) 24 (5.4%)
Death 7 (1.6%)
Neurologic death 2 (0.4%)
Cardiac death 3 (0.7%)
General death 2 (0.4%)
Stroke 20 (4.5%)
Ipsilateral stroke 15 (3.4%)
Major ischemic stroke 5 (1.1%)
Minor ischemic stroke 9 (2.0%)
Hemorrhagic stroked 1 (0.2%)
Contralateral stroke 5 (1.1%)
Major ischemic stroke 0 (0.0%)
Minor ischemic stroke 3 (0.7%)
Hemorrhagic stroked 2 (0.4%)
Subarachnoid hemorrhagic 0 (0.0%)
Q-wave MI 1 (0.2%)
Neurologic death, ipsilateral stroke (31-360 d) 14 (3.1%)
Neurologic death 7 (1.6%)
Ipsilateral stroke 11 (2.5%)
Major ischemic 6 (1.3%)
Minor ischemic 2 (0.4%)
Hemorrhagicd 3 (0.7%)
Restenosis rate (30 d)e 0 (0%)
Restenosis rate (360 d)e 40 (9.3%)
Target lesion revascularization rate (30 d) 0 (0.0%)
Target lesion revascularization rate (360 d) 20 (4.7%)
MI, Myocardial infarction; NA, not applicable.
aIpsilateral and contralateral are relative to the target lesion of the first proc
bIpsilateral and contralateral are relative to the target lesion of the second p
cP value corresponds to the comparison between outcomes for the pivotal g
dExcludes subarachnoid hemorrhage.
eRestenosis was defined as 70% diameter stenosis by duplex ultrasound.out in one surgical act is controversial,19-22 staged bilateralCEA with a few days in between procedures was shown to
be a safe and effective treatment concept.23,24 Rodriguez-
Lopez and colleagues analyzed outcomes of 77 patients
undergoing 154 bilateral CEAs within 4 days or less.24
Sixty-five percent of these patients were symptomatic. The
periprocedural transient ischemic attack (TIA) and stroke
rate were 2.6% and 0.7%, respectively, thereby comparing
favourably with a similarly composed group of patients
undergoing unilateral CEA.25 However, 30-day rates of
nerve injury and non-neurological complications such as
dysphagia and hoarseness due to trauma as well as haema-
tomas were 10.6% and 11%, respectively.24 Of note, ab-
sence of cranial nerve palsy is a major advantage of CAS
documented with level-A evidence.5
The feasibility of bilateral CAS was first reported by
Mathur and colleagues in 1997 26 and several case authors
described encouraging patient outcomes after bilateral
CAS for de novo stenoses,27 post-CEA carotid resteno-
ses,28,29 fibromuscular dysplasia,30 and Takayasu arteri-
tis.31 Henry and colleagues retrospectively analyzed out-
comes of 57 consecutive patients undergoing bilateral
CAS.12 In that series, 30% of patients underwent simulta-
l and bilateral group
ilateral first treated side
(n  78)a
Bilateral second treated side
(n  57)b Pc
5 (6.8%) 3 (5.8%) .66
0 (0.0%) 1 (1.9%) 1.00
3 (4.1%) 1 (1.9%) 1.00
0 (0.0%) 0 (0.0%) .60
0 (0.0%) 0 (0.0%) 1.00
0 (0.0%) 0 (0.0%) 1.00
0 (0.0%) 0 (0.0%) 1.00
3 (4.1%) 1 (1.9%) 1.00
1 (1.4%) 1 (1.9%) .71
0 (0.0%) 0 (0.0%) 1.00
1 (1.4%) 1 (1.9%) 1.00
0 (0.0%) 0 (0.0%) 1.00
2 (2.7%) 1 (1.9%) .26
0 (0.0%) 0 (0.0%) N/A
2 (2.7%) 1 (1.9%) .15
0 (0.0%) 0 (0.0%) 1.00
0 (0.0%) 0 (0.0%) N/A
0 (0.0%) 0 (0.0%) 1.00
3 (4.1%) 2 (3.8%) .72
1 (1.4%) 0 (0.0%) 1.00
2 (2.7%) 2 (3.8%) .70
0 (0.0%) 1 (1.9%) 1.00
2 (2.7%) 1 (1.9%) .09
0 (0.0%) 0 (0.0%) 1.00
1 (1.3%) 0 (0.0%) .14
9 (12.5%) 6 (12.0%) .39
0 (0%) 0 (0.0%) N/A
7 (9.7%) 6 (12.0%) .09
ure.
and first bilateral procedure.ivota
B
edure.
roced
roupneous CAS, whereas the remaining 70% were treated within
group
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symptomatic and embolic protection devices were used in
74% of patients. Incidence of stroke was 3.7%, and the rate
of the composite endpoint consisting of stroke, death, and
MI was 7.4% at 30 days.
To our knowledge, the present study represents the
largest consecutive series of patients undergoing staged
bilateral CAS in a prospective setting. We did not find
statistically significant differences with regard to the 30-day
and 12-month clinical outcomes comparing patients un-
dergoing unilateral with those receiving staged bilateral
CAS. The 30-day incidence of all strokes was 4.5% in the
pivotal and 4.1% in the bilateral group, while the 30-day
rate of ipsilateral stroke was 3.4% and 1.4%, respectively.
Furthermore, the 30-day rate for death, stroke, and Q-wave
MI was 5.4% in the pivotal and 4.1% in the bilateral group.
Also, no significant differences were found when compar-
ing ipsilateral stroke rates at 12 months. Thus, our results
corroborate findings from Henry’s retrospective series12
and compare well with findings in earlier CAS trials in
high-risk patients.5,32 In Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy
(SAPPHIRE), the 12-month incidence of all strokes was
6.2 after CAS and 7.9 after CEA, whereas the rate of
primary endpoint at 30 days (death, stroke, or MI plus
ipsilateral stroke or death from neurological causes within
31 days to 1 year) was 12.2% after CAS.5 Furthermore, in
the high-risk stent registry ACCULINK for Revasculariza-
tion of Carotids in High-Risk patients (ARCHeR), the
primary endpoint (a composite endpoint consisting of
death, stroke, and MI at 30 days plus ipsilateral stroke at 1
year) was 9.6%.32 In the Stent-protected Percutaneous
Angioplasty of the Carotid Endarterectomy (SPACE) trial,
definition of the primary endpoint was slightly different
compared with the ARCHeR and BEACH protocol,
thereby rendering a direct comparison across these trials
Table IV. Follow-up duplex ultrasound findings
Event
Pivotal
(N  480)a 95% CI
Bilater
treated
(N 
ICA/CCA ratio
Preprocedure 5.3  3.1 5.0-5.6 5.6 
Postprocedure 1.4  0.5 1.4-1.5 1.5 
1-mo 1.4  0.5 1.4-1.5 1.5 
6-mo 1.9  1.2 1.8-2.1 2.1 
1-y 1.9  1.1 1.8-2.0 1.8 
ICA-PSVmaximum
Preprocedure 346.1  148 332.2-360.0 373.7 
Postprocedure 115.8  40.7 112.1-119.6 123.6 
1-mo 109.7  37.6 106.2-113.2 111.6 
6-mo 146.9  73.5 139.8-154.1 151.7 
1-y 138.8  66.6 132.0-145.6 132.9 
CI, Confidence interval; SD, standard deviation; ICA/CCA, internal ca
maximum peak systolic velocity.
aNumbers are mean  SD.
bP value corresponds to the comparison between outcomes for the pivotaldifficult.33 However, the 30-day rate of all strokes was 7.7%after CAS and 6.5% after CEA in the SPACE study thereby
being slightly higher compared with that in the present
series. This observation, however, might be explained by
the facts that the SPACE trial contained only symptomatic
patients and that only 27% of patients were treated using an
embolic protection device.
Early restenosis was reported to occur in 10 % to 24% of
patients after carotid endarterectomy.34,35 Comparison of
restenosis rates after CAS and CEA between different trials
has been hampered by varying definitions and the lack of
reporting regarding symptomatic or asymptomatic sta-
tus.36 In various CAS trials, restenosis is usually defined
based upon some degree of duplex measurement with
secondary reporting of target vessel revascularization rates.
The Carotid and Vertebral Artery Transluminal Angio-
plasty Study (CAVATAS) trial, in which restenosis rates of
CAS and CEA were directly compared, used a cut-off
70% and reported a restenosis rate of 18.5% for CAS
compared with 5.2% for CEA.37 This trial used stents in
only 22% of the endovascular patients, while the remaining
88% were treated with angioplasty alone. Thus, the com-
paratively high restenosis rate in that trial was almost cer-
tainly caused by the use of inferior techniques of balloon
angioplasty during the early stages of development of ca-
rotid endovascular treatment in that trial.37 The BEACH
trial also used a cut-off of 70% and we found a 1-year
restenosis rate of 9.3% in the pivotal and 12.5% in the
bilateral group with differences not being statistically sig-
nificant. In a recent systematic review on restenosis after
CEA and CAS, the early restenosis rates after CAS compare
well with those reported for CEA.36 To date, only a few
studies have analyzed the restenosis rates after CAS beyond
2 years. Thus, data from further trials is warranted to assess
long-term patency rates of stented carotid arteries.
Shortcomings. Although in the present series FDA-
agreed OPCs for comparison with the current gold stan-
t
95% CI
Bilateral second
treated side
(N  57)a 95% CI Pb
4.7-6.4 4.8  2.4 3.9, 5.7 .48
1.3-1.6 1.4  0.6 1.2, 1.6 .45
1.3-1.6 1.3  0.4 1.2, 1.5 .58
1.7-2.6 1.8  0.7 1.5, 2.0 .37
1.5-2.2 1.7  0.6 1.5, 1.9 .66
337.7-409.7 343.6  144 291.1, 396.0 .15
5 111.9-135.3 121.3  50.0 106.9, 135.8 .22
7 100.9-122.3 103.7  28.9 95.1, 112.2 .74
5 129.1-174.3 142.5  65.3 120.5, 164.5 .69
6 115.0-150.9 148.2  67.2 124.1, 172.2 .54
artery/common carotid artery; ICA-PSVmaximum, Internal carotid artery
and first bilateral procedure.al firs
side
78)a
3.4
0.7
0.7
1.7
1.2
153
50.
45.
91.
68.
rotiddard, CEA, were used, this study does not contain a direct
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 6 Diehm et al 1233randomized comparison with open surgery. Furthermore,
the present study allowed CAS of the contralateral carotid
lesion only 30 days after endovascular treatment of the
primary target lesion. Thus, this study does not give insight
into patient outcomes after simultaneous bilateral CAS.
The concerns about simultaneous CAS seem to be the
hemodynamic impairment from stimulation of the carotid
sinus baroreflex and the risk of cerebral hyperperfusion
syndrome.38,39
Staged procedures have disadvantages including delay
of definitive treatment of carotid lesions, higher costs, and
inconvenience to the patient and could delay potentially
lifesaving procedures.12
CONCLUSIONS
In the present series, both the pivotal and the bilateral
group met the primary endpoint with a major adverse event
rate below the FDA-agreed OPC. Thus, staged bilateral
CAS is an efficient treatment option for patients at high
surgical risk and bilateral carotid artery stenoses and does
not yield inferior outcomes compared with unilateral stent-
ing. Data from further prospective studies is warranted to
confirm findings from the present study and to identify
subgroups of patients that are at particular high risk for
staged bilateral CAS.
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